{'fraction_non_alphanumeric': 0.033967391304347824, 'fraction_numerical': 0.004076086956521739, 'mean_word_length': 5.522123893805309, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Plasma levels of tumour necrosis factor‐α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis

Psoriasis (PsO) and psoriatic arthritis (PsA) are inflammatory disorders. Circulating biomarkers of inflammation such as interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), and C-reactive protein (CRP) have been associated with disease severity and progression of PsO and PsA. Adiponectin and leptin are adipose derived cytokines, recognized as key regulator of body weight and metabolism2 . Whether circulating levels of these inflammatory and metabolic biomarkers may predict the risk of PsA in psoriasis populations remains unclear. This article is protected by copyright. All rights reserved.